Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer

University of Alberta

$65,000.00

Understanding why some breast cancers resist reovirus oncolysis and expanding reovirus as a cancer therapy towards resistant breast cancers

EF 2023-24

Résumé
Breast cancer (BC) accounts for a significant portion of new cancer cases and deaths in Canadian women. Reovirus, a virus harmless to humans, has shown promise in reducing BC tumors and stimulating immune responses. However, fewer than 20% of BC patients respond to it. that BC cells lacking the protein JAM-A resist reovirus, while a modified version, s1?Head, can infect these cells. This study aims to understand why s1?Head is effective in JAM-A-deficient BC cells and evaluate its therapeutic potential in BC animal models with low JAM-A levels. Also, we will discover how much JAM-A is required for reovirus treatment to help guide personalized treatment decisions. By tailoring reovirus for cancer cells based on factors like JAM-A, we aim to unleash the full potential of reovirus for BC therapy.
Programme
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
516999
Name
Shmulevitz Maya
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Understanding why some breast cancers resist reovirus oncolysis and expanding reovirus as a cancer therapy towards resistant breast cancers
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
Breast cancer (BC) accounts for a significant portion of new cancer cases and deaths in Canadian women. Reovirus, a virus harmless to humans, has shown promise in reducing BC tumors and stimulating immune responses. However, fewer than 20% of BC patients respond to it. that BC cells lacking the protein JAM-A resist reovirus, while a modified version, s1?Head, can infect these cells. This study aims to understand why s1?Head is effective in JAM-A-deficient BC cells and evaluate its therapeutic potential in BC animal models with low JAM-A levels. Also, we will discover how much JAM-A is required for reovirus treatment to help guide personalized treatment decisions. By tailoring reovirus for cancer cells based on factors like JAM-A, we aim to unleash the full potential of reovirus for BC therapy.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Shmulevitz, Maya
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~